The stock of Cogentix Medical Inc (NASDAQ:CGNT) hit a new 52-week high and has $2.94 target or 7.00% above today’s $2.75 share price. The 8 months bullish chart indicates low risk for the $199.57 million company. The 1-year high was reported on Dec, 1 by Barchart.com. If the $2.94 price target is reached, the company will be worth $13.97 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 478,153 shares traded hands or 206.99% up from the average. Cogentix Medical Inc (NASDAQ:CGNT) has risen 147.62% since April 28, 2016 and is uptrending. It has outperformed by 141.69% the S&P500.
Cogentix Medical Inc (NASDAQ:CGNT) Ratings Coverage
Out of 2 analysts covering Cogentix Medical (NASDAQ:CGNT), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cogentix Medical has been the topic of 3 analyst reports since November 5, 2015 according to StockzIntelligence Inc. The rating was upgraded by Roth Capital to “Buy” on Thursday, November 5. The company was downgraded on Friday, May 6 by Roth Capital. The stock has “Buy” rating given by TH Capital on Thursday, November 5.
According to Zacks Investment Research, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York.”
More notable recent Cogentix Medical Inc (NASDAQ:CGNT) news were published by: Prnewswire.com which released: “Cogentix Medical Enters Into Definitive Agreement For $25 Million Equity …” on September 07, 2016, also Prnewswire.com with their article: “Cogentix Medical Shareholders Approve $25 Million Equity Investment” published on November 03, 2016, Prnewswire.com published: “Cogentix Medical Announces Settlement Agreement in Connection with Proxy …” on May 24, 2016. More interesting news about Cogentix Medical Inc (NASDAQ:CGNT) were released by: Prnewswire.com and their article: “Brett Reynolds Rejoins Cogentix Medical As Chief Financial Officer” published on June 15, 2016 as well as Prnewswire.com‘s news article titled: “Darin Hammers Appointed President And CEO Of Cogentix Medical, Inc.” with publication date: July 12, 2016.
CGNT Company Profile
Cogentix Medical, Inc., incorporated on October 19, 1987, is a global medical device company. The Firm designs, develops, makes and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Firm also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office treatment of overactive bladder (OAB). The Firm also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.